Sublocade® (buprenorphine extended-release)
| Full Name | Sublocade® (buprenorphine extended-release) |
| Drug | Sublocade |
| Manufacturer | Indivior |
| Route of Administration | Subcutaneous |
| Site of Care | Healthcare Facility |
| Approved Indication | The treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a transmucosal buprenorphine-containing product, followed by dose adjustment for a minimum of 7 days |
| Disease | Opioid Dependence |
| Therapeutic Area | Mental Health & Addiction |
| Enrollment Form Link | Sublocade Enrollment Form |
| Phone Number | 800-241-1534 |
| Fax Number | 877-785-7737 |
| Product Website | sublocade.com |